ArticleNPJ biofilms and microbiomes2025
In vitro assessment of bacterial supernatants on hypothalamic gene expression: implications for appetite regulation.
Article in NPJ biofilms and microbiomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epigenetic regulation by gut microbiota-derived metabolites in celiac disease.Biochemistry and biophysics reports · 2026Review
- Bifidobacterium longum and prebiotic interventions restore early-life high-fat/high-sugar diet-induced alterations in feeding behavior in adult mice.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Bacterial metabolites, such as short-chain fatty acids (SCFAs), influence energy balance, appetite, and endocrine function. Investigating cell-free (CFSs) and cell-free conditioned supernatants (CCSs) containing SCFAs and other microbial metabolites may help unravel the mechanisms underpinning these potential benefits for metabolic health. This study evaluated the neuroactive potential of two bacterial species, Bifidobacterium longum APC1472 and Limosilactobacillus reuteri ATCC PTA 6475, known for their metabolic health benefits. In silico analysis predicted the capacity of these bacteria to produce neuroactive metabolites involved in gut-brain communication. Next, untargeted metabolomics was used to evaluate the predicted functional capability of these two species to produce metabolites under different growth conditions. CFSs and CCSs were tested on embryonic and adult mouse hypothalamic cells to assess their effects on appetite-regulating gene expression. Results revealed supernatant type- and species-specific metabolite profiles, identifying B. longum APC1472 and L. reuteri ATCC PTA 6475 as acetate producers, with B. longum APC1472 also identified as a tryptophan producer. The distinct metabolite profiles of CFSs and CCSs from these two species induced specific effects on the modulation of ghrelin receptor and glucagon-like receptor 1 gene expression in hypothalamic cells. These findings validate an in vitro approach to identify bacterial metabolites with potential neuroactive and metabolic health benefits, demonstrated through modulation of mouse hypothalamic gene expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.